Tenet Healthcare Continues To Win In Q2, But Medicaid Cuts May Threaten Growth Beyond 2026

Tenet Healthcare (THC) reported a strong Q2, significantly exceeding estimates with $5.27 billion in revenue and $4.02 non-GAAP EPS, and subsequently raised its full-year guidance to $20.95-$21.25 billion revenue and $15.55-$16.21 non-GAAP EPS. This positive performance is driven by growth in its higher-margin ambulatory segment, a strategic move to limit exposure to the looming $1 trillion Medicaid cuts set to impact the broader healthcare sector from 2027. While THC has actively mitigated risk by shifting away from Medicaid-exposed hospital services, its remaining hospital operations face considerable uncertainty from these substantial policy changes, suggesting a mixed long-term outlook despite near-term strength.

Analysis

Tenet Healthcare (THC) delivered a significant Q2 earnings beat, with revenue of $5.27 billion surpassing estimates of $5.16 billion and non-GAAP EPS of $4.02 well ahead of the $2.88 consensus. This outperformance is consistent with a multi-year trend. The primary driver of this strength is the continued growth in the higher-margin Ambulatory segment, which is strategically less exposed to Medicaid. Conversely, the Hospital segment experienced a revenue decline, although cost efficiencies led to EBITDA growth in that segment as well. Despite the strong operational results and raised full-year guidance—projecting revenue of $20.95-$21.25 billion and non-GAAP EPS of $15.55-$16.21—a major long-term headwind looms. A newly passed budget mandates a $1 trillion cut to Medicaid over ten years, with major eligibility changes taking effect after the 2026 midterm elections. This poses a substantial risk to THC's hospital operations, which remain a large part of its business. The market's cautious reaction, with the stock declining post-earnings, reflects this tension between strong near-term execution and significant long-term policy uncertainty. At a forward P/E ratio of approximately 10, THC trades at a considerable discount to the sector median of 16.97, presenting a value case for investors willing to look past the future legislative risks.

Key Decisions for Investors

• Investors should weigh Tenet's strong near-term performance and raised 2025 guidance against the significant, though delayed, legislative risk from Medicaid cuts scheduled to take effect in 2027.
• The primary metric to monitor is the growth of the Ambulatory segment's share of total revenue, as this is the company's key strategy to mitigate exposure to long-term policy headwinds.
• Given the forward P/E discount relative to the sector, value-oriented investors may see an opportunity, but this requires a high tolerance for policy uncertainty impacting the Hospital segment.
• For those with lower risk appetite, it may be prudent to limit exposure to the healthcare provider sector entirely until the full impact and implementation of the Medicaid cuts become clearer.